Transasia Bio-Medicals’ international hematology range backed by European R&D is now in Tamil Nadu
Transasia Bio-Medicals’ international hematology range backed by European R&D is now in Tamil Nadu; to base its next hi-tech manufacturing facility in the South. Priced 25% below comparable options, new range to make world-class diagnostics affordable for masses.
- (1888PressRelease) June 04, 2019 - Transasia Bio-Medicals Ltd., India's No. 1 In-vitro Diagnostic (IVD) Company and among the leading global players focused on emerging markets, today as part of its 40th anniversary celebration announced that its international hematology range, is now available in Tamil Nadu. Backed by European R&D, the 3-Part Differential Analyzer (3PDA) to 5-Part Differential Analyzer (5PDA) fully automated haematology analyzers, reagents and controls include a number of features to help institutions, clinicians and lab technologists offer accurate diagnosis. Manufactured by Erba Lachema (100% owned subsidiary of Transasia) in Europe, the H 360, H 560 and ELite 580 hematology analyzers are widely used in the European and global market. Hematology analyzers are extensively used in patient and research settings to count and characterize blood cells for disease detection and monitoring. Basic analyzers return a complete blood count (CBC) with a three-part differential white blood cell (WBC) count. Sophisticated analyzers measure cell morphology and can detect small cell populations to diagnose rare blood conditions.
The new hematology range offers additional parameters, besides the routine ones like Platelet Large Cell Ratio (PLCR) and Platelet Large Cell Concentration (PLCC), that aid in enumeration of large or ‘giant’ platelets. The instruments thus become very relevant for Tamil Nadu, which attracts migrant labor from rural parts of Eastern India (West Bengal and the nearby areas), where large platelets are prevalently seen in the blood samples, and are commonly associated with certain blood disorders. Moreover, these parameters can be useful in differentiating conditions such as thrombocytosis (high platelet count) and thrombocytopenia (low platelet count), amongst others. Anemia, due to malnutrition continues to be a pain point for the women of Tamil Nadu. Also, in certain pockets of Salem, large number of cases of thalassemia and sickle cell anemia are evident. Transasia’s new range can play a vital role in their accurate diagnosis especially in remote areas.
Addressing the media, Mala Vazirani, Executive Director, Transasia Bio-Medicals Ltd., said, “We are glad to be introducing our hematology range, here today. Tamil Nadu holds the No. 1 spot in Indian healthcare due to the existence of large and successful base of medical teaching institutes in Chennai and the nearby areas. The state also has the unique distinction of most successful implementation of Government healthcare schemes under Public-Private Partnerships (PPP) as well as direct implementation of programs such as National Health Mission (NHM).” “As per industry reports in 2018, India's medical devices industry is pegged at a $5.2 billion (Rs. 35,097.40 crore), most of which is imported. It is players like Transasia who are at the forefront of changing it and driving Make in India,” she further added.
In his comments, Anil Jotwani, Senior Advisor, Transasia, said, “The Tamil Nadu Government has always trusted Transasia for its quality products and reliable results. Transasia has been closely associated with Tamil Nadu Medical Service Corporation Ltd. (TNMSC) for the successful implementation and execution of the hematology and biochemistry testing programs in rural areas. Also, Transasia actively collaborated with Amma Healthcare Initiatives to make them a grand success.”
India ranks 145th among 176 countries on the quality and accessibility of healthcare parameter. Limited access to quality medical infrastructure, including skilled manpower and technologies have been the pain points of over 70% of Indians who live in smaller towns and rural areas. Transasia has been focusing on indigenous development & technology adoption which facilitates affordable diagnostics through domestic manufacturing.
Talking about the newly launched range, Dr. Avi Nahar, M.D. Pathology, Business Unit Head – Hematology, Transasia said, “Accepted world-over for their quality, precision and ease-of-operation, the Erba range of hematology products will increase the adoption of automated hematology testing among Indian diagnostic labs. The range provides holistic solutions for clinical testing in general and targeted diagnostics which is an added advantage for pediatric and geriatric population. Other unique features include flagging of abnormal samples, RFID, large colored LCD touch screen, customizable reporting formats, ability to connect to a Laboratory Information System (LIS) for result output and ready-to-use reagents that are cyanide free and environment-friendly. By addressing many challenges that labs and pathologists face, Transasia is helping healthcare professionals (HCPs) focus on giving patients the best possible care.”
About Transasia Bio-Medicals Ltd.: Founded in 1979, Transasia Bio-Medicals Ltd., India’s Leading In-vitro Diagnostic Company offers products and solutions in Biochemistry, Hematology, Coagulation, ESR, Immunology, Urinalysis, Critical Care, Diabetes Management, Microbiology and Molecular Diagnostics. Transasia provides doctors and patients with reliable, affordable and innovative Medical Diagnostic Systems, with an impressive install base of above 65,000 equipment across India. It has a vast network of the more than 250 service engineers, 400+ sales and marketing team, 23 zonal offices and 350+ distributors. It is the first Indian company to manufacture and export blood analyzers and reagents, in the 1990s. Today, Transasia’s indigenous research has resulted in development of state of the art, ‘Make in India’ products and technologies, enabling its products to be among the best in the world. All along its journey spanning more than four decades, Transasia has been recognized for its commitment to healthcare. It has been conferred ‘The Economic Times Best Brands 2019’ award, ‘India Medical Device - Export Company of the Year’ and the ‘Global Growth Company-2014’ award by the World Economic Forum amongst many others. Headquartered in Mumbai, Transasia is a part of the global Transasia-Erba group. The group has spread its footprint across USA, UK, Germany, Czech Republic, France, Italy, Russia and Turkey through various acquisitions. Transasia-Erba Group’s production sites in India, Czech Republic and USA and R&D centres in France, UK, India and Czech Republic form a hub for indigenous manufacturing of world class deliverables. Today, the group serves millions across 100 countries. For further information, kindly visit www.erbamannheim.com
For editorial queries only contact Anurag of PRHUB @ 9322501136/anurag ( @ ) prhub dot com.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam